Gain Therapeutics, Inc. $GANX

By Microcap Ledger desk · CIK 0001819411

Facts as of Oct 11, 2026, 08:11 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Market
Sector: Pharmaceutical Preparations
Headquarters: Bethesda, MD
Fiscal year end: December 31
Shares outstanding: 43,643,619 [10-Q 2026-08-11]
as of 2026-07-31

Sources: [10-K 2026-03-26]

What the company doesAI summary of filing

Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics for central nervous system disorders, lysosomal storage disorders, metabolic disorders, and oncology. Its lead product candidate, GT-02287, is being evaluated in a Phase 1b clinical trial for Parkinson's disease in patients with or without GBA1 mutations and has completed Phase 1 safety studies in healthy volunteers. The company uses its proprietary Magellan computational platform to discover novel allosteric binding sites on disease-related proteins and identify small molecules that bind to these sites to modulate protein function. Gain has no product revenues and is in the clinical development stage. [10-K 2026-03-26]

Segments: GT-02287 (Parkinson's disease, GBA1-related diseases)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$10.28M	−$9.41M	$13.08M	[10-Q 2026-08-11]
FY ended Dec 2025	—	−$20.16M	−$18.47M	$20.84M	[10-K 2026-03-26]
FY ended Dec 2024	—	−$20.41M	−$18.87M	$10.39M	[10-K 2026-03-26]

Quarterly cash burn: −$4.70M
Cash runway Estimate: ~8.3 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-10-31	26,525,068	[10-Q 2024-11-14]
2025-02-28	27,786,952	[10-K 2025-03-27]
2025-04-30	29,557,640	[10-Q 2025-05-14]
2025-07-31	35,948,606	[10-Q 2025-08-12]
2025-10-31	36,097,536	[10-Q 2025-11-12]
2026-02-28	42,241,947	[10-K 2026-03-26]
2026-04-30	42,654,038	[10-Q 2026-05-11]
2026-07-31	43,643,619	[10-Q 2026-08-11]

Shelf registration: S-3 filed 2025-05-28; no effectiveness notice found in EDGAR [S-3 2025-05-28]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-15. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-01-15	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-01-15]

More on deficiency notices and uplistings: Listing status desk.

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-01	8-K	Other events
2026-09-28	8-K	Director or officer change
2026-08-11	10-Q	Quarterly report
2026-08-11	8-K	Results of operations
2026-07-16	8-K	Other events
2026-06-29	8-K	Other events
2026-06-25	8-K	Shareholder vote results
2026-05-26	8-K	Other events
2026-05-11	10-Q	Quarterly report
2026-05-11	8-K	Results of operations
2026-04-28	DEF 14A	Proxy statement
2026-03-26	10-K	Annual report

Facts as of Oct 11, 2026, 08:11 AM UTC. Small caps move fast; check the latest filings.